Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : CSC-RR0381
Host Cell : BxPC3 Size : >1x106 frozen cells/vial
| Cat. No. | CSC-RR0381 |
| Description | This cell line is engineered to stably overexpress the Luciferase in BXPC-3 cells. |
| Introduction | BXPC-3-Luc cell line is constructed by stable integration of luciferase encoding gene into BXPC-3 cell genome. It is a good cell model for in vitro or in vivo cancer research. |
| Target Gene | Luciferase |
| Host Cell | BxPC3 |
| Host Cell Species | Homo sapiens (Human) |
| Source | BXPC-3 |
| Applications |
1. Gene expression studies 2. Protein localization 3. Drug screening and toxicology 4. Live cell imaging |
| Size | >1x106 frozen cells/vial |
| Stability | Validated for at least 10 passages |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Storage | Liquid nitrogen |
| Shipping | Dry ice |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
The Luciferase Reporter Cell Line - BXPC-3 is a specialized cell model engineered to express the luciferase gene, which serves as a bioluminescent reporter for monitoring gene expression and cellular responses. Luciferase, derived from the Latin word "lucifer," meaning "light-bringing," is an enzyme that catalyzes the oxidation of luciferin, resulting in the emission of light. This property makes it an ideal marker for studying gene expression, as the intensity of light produced is proportional to the amount of luciferase, and thus the activity of the promoter driving its expression.
The BXPC-3 cell line, originating from a human pancreatic carcinoma, is a well-established model for pancreatic cancer research. When this cell line is modified to stably express the luciferase gene, it becomes a powerful tool for studying the molecular mechanisms underlying pancreatic cancer progression, metastasis, and response to therapeutic agents. Researchers can use this cell line to screen for compounds that modulate gene expression, identify potential drug targets, and evaluate the efficacy of novel therapeutic strategies in a preclinical setting.
One of the most aggressive cancers still is pancreatic cancer (PC), which is defined by a bad prognosis and few treatment choices. To improve diagnostic and therapy effectiveness, researchers have been investigating molecular markers and focused treatments. In this setting, a recent work examined the function of microRNA-543 in PC, including its interaction with the serine/threonine kinase STK31 and the long non-coding RNA LINC00847. Using the BxPC-3 cell line, researchers clarified the fundamental processes controlling cell proliferation, invasion, and death using Western blotting, quantitative real-time PCR, and luciferase reporter assays. The findings revealed that low levels of microRNA-543 correlate with increased expression of STK31 and LINC00847, highlighting a potential pathway for therapeutic intervention.
Figure 1. The researchers used qRT-PCR and Western blotting to analyze STK31 expression in pancreatic cancer tissues and BxPC-3 cells, exploring its interaction with microRNA-543. (Liu Y, et al., 2023)
Creative Biogene's luciferase Reporter Cell Line, based on the BXPC-3 model, is designed for similar investigative purposes. This cell line can facilitate the study of gene regulation and signaling pathways in pancreatic cancer research, especially in relation to microRNA functions and their molecular targets. By integrating our luciferase reporter technology, researchers can easily monitor transcriptional activity and understand the dynamic interactions between microRNAs and their targets.
Luciferase Reporter Cell Line - BXPC-3
The Luciferase Reporter Cell Line - BXPC-3 is a pancreatic cancer cell line engineered to express the luciferase gene, which allows for the bioluminescent measurement of cellular activity and gene expression. This cell line is particularly useful for studying the behavior of pancreatic cancer cells and for the development of novel therapeutic strategies.
(1)Cancer Progression and Metastasis Research:
The BXPC-3 cell line can be utilized to investigate the mechanisms of cancer progression and metastasis. By monitoring luciferase activity, researchers can track the growth and spread of pancreatic cancer cells both in vitro and in vivo, providing valuable insights into the biology of this aggressive disease.
(2)Drug Screening and Development:
The luciferase reporter system in BXPC-3 cells enables high-throughput screening of compounds for their potential to inhibit pancreatic cancer cell growth. Researchers can assess the efficacy of new drugs and identify potential therapeutic agents that target specific cellular processes or pathways involved in cancer progression.
(3)Gene Function and Signaling Pathway Analysis:
The BXPC-3 Luciferase Reporter Cell Line can be used to study the function of genes and signaling pathways that are dysregulated in pancreatic cancer. By manipulating gene expression and observing changes in luciferase activity, researchers can gain a better understanding of the molecular mechanisms underlying cancer development and identify potential therapeutic targets.
A: The Luciferase Reporter Cell Line - BXPC-3 serves as a valuable tool for investigating pancreatic cancer progression and therapeutic response. By expressing luciferase, researchers can quantitatively monitor tumor growth and metastasis in vivo using bioluminescence imaging. This allows for the evaluation of experimental therapies and the identification of potential treatments for pancreatic cancer.
A: The Luciferase Reporter Cell Line - BXPC-3 offers several advantages over traditional cell lines in studying pancreatic cancer biology. Firstly, its stable expression of luciferase enables longitudinal monitoring of tumor growth and metastasis in vivo, providing insights into disease progression. Secondly, BXPC-3 cells retain characteristics of pancreatic cancer cells, making them a relevant model for investigating disease mechanisms and therapeutic interventions.
A: In investigating the efficacy of novel chemotherapeutic agents for pancreatic cancer treatment, the Luciferase Reporter Cell Line - BXPC-3 can be used to evaluate tumor response in preclinical studies. Researchers can administer candidate drugs to mice bearing BXPC-3 xenograft tumors and monitor changes in luciferase activity over time using bioluminescence imaging. This allows for the identification of promising drug candidates for further development.
A: The Luciferase Reporter Cell Line - BXPC-3 is instrumental in studying the tumor microenvironment of pancreatic cancer. By co-culturing BXPC-3 cells with stromal cells or immune cells, researchers can investigate the interactions between tumor cells and the surrounding microenvironment. Luciferase expression enables quantification of changes in tumor growth and response to microenvironmental cues or therapeutic interventions, providing insights into disease progression and treatment strategies.
A: Generating stable luciferase-expressing cell lines with the Luciferase Reporter Cell Line - BXPC-3 involves transfecting the cells with a luciferase expression vector, followed by selection with antibiotics or selection markers. Clonal selection may be performed to isolate individual clones with stable luciferase expression. These clones can then be expanded and characterized for their luciferase activity before experimental use in studying pancreatic cancer biology and therapy.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The BXPC-3 cells are relatively easy to culture and maintain, ensuring that the Luciferase Reporter Cell Line - BXPC-3 is accessible for continuous use in various experimental conditions, reducing the complexity of long-term studies.
Luciferase assays are quick and straightforward, meaning the Luciferase Reporter Cell Line - BXPC-3 can deliver rapid results, accelerating the experimental workflow and facilitating high-throughput screening.
With the Luciferase Reporter Cell Line - BXPC-3, we can efficiently screen for therapeutic agents by measuring changes in luciferase activity, making it an excellent tool for drug discovery in pancreatic cancer.
The Luciferase Reporter Cell Line - BXPC-3 provides quantifiable luminescent output, enabling precise measurement of cellular activities that correlate with luciferase expression, essential for reproducible results and accurate data analysis.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.